HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. Journal Of Clinical Oncology 2016, 35: 446-464. PMID: 28129524, DOI: 10.1200/jco.2016.69.4836.Peer-Reviewed Original ResearchConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical OncologyAmerican SocietyClinical decisionClinical pathologyAmerican PathologistsAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Archives Of Pathology & Laboratory Medicine 2016, 140: 1345-1363. PMID: 27841667, DOI: 10.5858/arpa.2016-0331-cp.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiomarkers, TumorClinical Decision-MakingCombined Modality TherapyDecision TreesDiagnosis, DifferentialEsophageal NeoplasmsEvidence-Based MedicineHumansMedical OncologyMolecular Diagnostic TechniquesMolecular Targeted TherapyMutationNeoplasm GradingNeoplasm StagingPathology, ClinicalReceptor, ErbB-2Societies, MedicalStomach NeoplasmsSystematic Reviews as TopicUnited StatesConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical OncologyAmerican SocietyClinical decisionClinical pathologyAmerican PathologistsAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. American Journal Of Clinical Pathology 2016, 146: 647-669. PMID: 28077399, PMCID: PMC6272805, DOI: 10.1093/ajcp/aqw206.Peer-Reviewed Original ResearchConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical decisionAmerican SocietyAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingClinical OncologyTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyClinical pathologyAmerican PathologistsVaried autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells
Monestime G, Borger DK, Kim J, Lopez G, Allgaeuer M, Jain D, Vortmeyer A, Wang HW, Sidransky E. Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells. Molecular Genetics And Metabolism 2016, 118: 55-59. PMID: 26992326, DOI: 10.1016/j.ymgme.2016.02.008.Peer-Reviewed Original ResearchConceptsAutopsy findingsGaucher diseaseDose/durationEnzyme replacement therapySpleen statusPathological findingsReplacement therapyDisease burdenPathological studiesGaucher cellsPatientsHematological symptomsExtensive involvementTherapyParkinsonismDiseaseMultiple tissuesComplete absenceFindingsAutopsiesSymptomsPathologyBiomarkersCare